Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies

Daniel Re, Barbara Seitz-Polski, Michel Carles, Vesna Brglez, Daisy Graça, Sylvia Benzaken, Stéphane Liguori, Khaled Zahreddine, Margaux Delforge, Benjamin Verrière, Emmanuel Chamorey, Barrière Jérôme
doi: https://doi.org/10.1101/2021.07.18.21260669
Daniel Re
1Department of Hematology and Medical Oncology, Centre Hospitalier Antibes-Juan les Pins, 107 Route de Nice, 06600 Antibes, FRANCE
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: daniel.re{at}ch-antibes.fr j.barriere{at}polesantesaintjean.fr
Barbara Seitz-Polski
2Laboratoire d’Immunologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d’Azur, Nice, France
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Carles
3Department of infectious disease, Centre Hospitalo-Universitaire de Nice, ARCHET 1 06000 NICE, France
MD., Ph D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vesna Brglez
2Laboratoire d’Immunologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d’Azur, Nice, France
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daisy Graça
4Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, CHU de Nice, Université Côte d’Azur, Nice, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvia Benzaken
4Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, CHU de Nice, Université Côte d’Azur, Nice, France
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphane Liguori
5Department of Medical Biology, Centre Hospitalier, Antibes, France
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khaled Zahreddine
5Department of Medical Biology, Centre Hospitalier, Antibes, France
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaux Delforge
6Department of Pharmacy, Centre Hospitalier, Antibes, France
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Verrière
6Department of Pharmacy, Centre Hospitalier, Antibes, France
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuel Chamorey
7Department of Biostatistics and Epidemiology., Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France
PharmD., PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barrière Jérôme
8Department of Medical Oncology, Polyclinique Saint Jean, 92 avenue Dr Donat, 06800 Cagnes-sur-Mer, France
MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: daniel.re{at}ch-antibes.fr j.barriere{at}polesantesaintjean.fr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

BACKGROUND Immunocompromised patients such as patients with hematological malignancies have impaired immune response to two doses of BNT162b2 (Pfizer / BioNtech) vaccine against SARS-CoV-2. Evaluation of a repeated immune stimulation with a third vaccine dose is needed.

METHODS a vaccine monitoring observatory was conducted in outpatients who were treated for lymphoid malignancies (LM) to monitor both immune and cellular response measured the day of administration of the dose 3 of the mRNA vaccine BNT162b2 and again three to four weeks. Elecsys ® Anti-SARS-CoV-2 immunoassay was used to asses to the level of SARS-CoV-2 anti-Spike (S) antibodies (Abs) titer and SARS-CoV-2-specific T-cell responses were assessed by a whole blood Interferon-Gamma Release Immuno Assay (IGRA) (QuantiFERON Human IFN-gamma SARS-CoV-2, Qiagen®).

RESULTS Among the 43 assessable patients (suffering from chronic lymphocytic leukemia (CLL) (n=15), indolent and aggressive B cell non-Hodgkin lymphoma (NHL) (n=14), and multiple myeloma (MM) (n=16)), 18 (41,8%) had no anti-S Abs before the dose 3 of BNT162b2 vaccine (n=9 CLL, n=8 NHL, n=1 MM), and they all 18 remained negative after the dose 3. Amongst the 25 patients with positive anti-S titers before dose 3, all patients remained positive and 23 patients increased their anti-S titer after dose 3. Patients with CLL and/or with previous anti-CD20 therapy treated within 12 months of administration of dose 3 had no significant increase of the humoral response. Among 22 available patients, dose 3 of BNT162b2 vaccine significantly increased the median IFN-gamma secretion. On eight (36.4%) patients who were double-negative for both immune and cellular response, five (22.7%) patients remained double-negative after dose 3.

CONCLUSIONS Dose 3 of BNT162b2 vaccine stimulated humoral immune response among patients with LM, in particular patients with MM (who had higher anti-S baseline titer after dose 2) and those with no anti-CD20 treatment history within a year. T-cell response was increased among patients in particular with no active chemotherapy regimen. Our data support the use of an early third vaccine dose among immunocompromised patients followed for LM though some of them will still have vaccine failure.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

All participants signed a written informed consent and accepted their participation in this registered trial in accordance with ethical and legal French policies (Registration number F20210324145532)

Funding Statement

This research was supported by a grant from Conseil Departemental des Alpes-Maritimes and from the Agence Nationale pour la Recherche AO-Flash-COVID.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The third dose was made according to the French National Authority for health (ref 10) published on April 11th 2021 recommending the use of a third dose in immunosuppressed patients. The current study has been discussed with the president of the local ethics committee of the Antibes hospital where all patients were followed and vaccinated (Dr Philippe de Swardt philippe.deswardt{at}ch-antibes.fr). Dr de Swardt decided that the current observatory was conducted according to the French policies and therefore that a formal local or national CPP (Comite de protection des personnes) statement was not necessary according to French policies. However, all participants signed a written informed consent and accepted their participation in this registered observatory in accordance with ethical and legal French policies (Registration number F20210324145532). All data were prospectively collected on an electronic anonymous data set.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • daniel.re{at}ch-antibes.fr

  • seitz-polski.b{at}chu-nice.fr

  • Carles.m{at}chu-nice.fr

  • brglez.v{at}chu-nice.fr

  • graca.d{at}chu-nice.fr

  • benzaken.s{at}chu-nice.fr

  • stephane.liguori{at}ch-antibes.fr

  • Khaled.zahreddine{at}ch-antibes.fr

  • margaux.delforge{at}ch-antibes.fr

  • benjamin.verriere{at}ch-antibes.fr

  • Emmanuel.chamorey{at}nice.unicancer.fr

  • j.barriere{at}polesantesaintjean.fr

  • j.barriere{at}polesantesaintjean.fr

  • Concept and design: All authors.

  • Acquisition, analysis, or interpretation of data: All authors.

  • Drafting of the manuscript: Drs Re, Seitz-Polski, Carles, Chamorey and Barrière.

  • Critical revision of the manuscript for important intellectual content: All authors.

  • Statistical analysis: Dr Seitz-Polski and Chamorey

  • Administrative, technical, or material support: All authors.

  • Supervision: Drs Re and Dr Barriere.

  • Conflict of Interest Disclosures: No disclosures were reported.

  • Funding/Support: This research was supported by a grant from Conseil Départemental des Alpes-Maritimes and from the Agence Nationale pour la Recherche AO-Flash-COVID.

  • Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

  • Disclaimer: The analyses described are the responsibility of the authors and do not necessarily reflect the views or policies of the US Department of Health and Human Services. The mention of trade names, commercial products, or organizations does not imply endorsement by the US government.

Data Availability

all data are available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 22, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies
Daniel Re, Barbara Seitz-Polski, Michel Carles, Vesna Brglez, Daisy Graça, Sylvia Benzaken, Stéphane Liguori, Khaled Zahreddine, Margaux Delforge, Benjamin Verrière, Emmanuel Chamorey, Barrière Jérôme
medRxiv 2021.07.18.21260669; doi: https://doi.org/10.1101/2021.07.18.21260669
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies
Daniel Re, Barbara Seitz-Polski, Michel Carles, Vesna Brglez, Daisy Graça, Sylvia Benzaken, Stéphane Liguori, Khaled Zahreddine, Margaux Delforge, Benjamin Verrière, Emmanuel Chamorey, Barrière Jérôme
medRxiv 2021.07.18.21260669; doi: https://doi.org/10.1101/2021.07.18.21260669

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (431)
  • Allergy and Immunology (757)
  • Anesthesia (221)
  • Cardiovascular Medicine (3302)
  • Dentistry and Oral Medicine (365)
  • Dermatology (281)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1174)
  • Epidemiology (13389)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5163)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3277)
  • Health Policy (1143)
  • Health Systems and Quality Improvement (1194)
  • Hematology (432)
  • HIV/AIDS (1019)
  • Infectious Diseases (except HIV/AIDS) (14642)
  • Intensive Care and Critical Care Medicine (914)
  • Medical Education (478)
  • Medical Ethics (127)
  • Nephrology (525)
  • Neurology (4934)
  • Nursing (262)
  • Nutrition (732)
  • Obstetrics and Gynecology (886)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (729)
  • Orthopedics (282)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (545)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4219)
  • Public and Global Health (7514)
  • Radiology and Imaging (1708)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (425)
  • Surgery (550)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)